MYOTONIC DYSTROPHY 1
Clinical trials for MYOTONIC DYSTROPHY 1 explained in plain language.
Never miss a new study
Get alerted when new MYOTONIC DYSTROPHY 1 trials appear
Sign up with your email to follow new studies for MYOTONIC DYSTROPHY 1, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for muscle stiffness: experimental drug PGN-EDODM1 enters Mid-Stage trial
Disease control Recruiting nowThis study tests an investigational drug called PGN-EDODM1 in 24 adults with myotonic dystrophy type 1, a condition causing muscle stiffness and weakness. Participants receive multiple doses of the drug or a placebo by IV to check safety and how the body processes it. The goal is…
Matched conditions: MYOTONIC DYSTROPHY 1
Phase: PHASE2 • Sponsor: PepGen Inc • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New hope for DM1: Long-Term safety trial of PGN-EDODM1 now recruiting
Disease control Recruiting nowThis study is testing the long-term safety of an experimental drug called PGN-EDODM1 in 48 adults with myotonic dystrophy type 1 (DM1) who have already taken the drug in a previous study. Participants will receive the drug by IV infusion and be monitored for side effects. The goa…
Matched conditions: MYOTONIC DYSTROPHY 1
Phase: PHASE2 • Sponsor: PepGen Inc • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New hope for muscle stiffness: experimental drug ATX-01 enters human trials
Disease control Recruiting nowThis study tests a new drug called ATX-01 in 56 adults with myotonic dystrophy type 1, a condition that causes muscle stiffness and weakness. The drug aims to block a molecule that may contribute to the disease. The trial will first give a single dose, then multiple doses, to che…
Matched conditions: MYOTONIC DYSTROPHY 1
Phase: PHASE1, PHASE2 • Sponsor: ARTHEx Biotech S.L. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New hope for muscle disease: experimental drug ARO-DM1 enters human trials
Disease control Recruiting nowThis study tests a new drug called ARO-DM1 in 78 adults aged 18-65 with type 1 myotonic dystrophy, a genetic muscle disorder. The goal is to check safety and how the body processes the drug. Participants receive either ARO-DM1 or a placebo by IV or injection. It is an early-stage…
Matched conditions: MYOTONIC DYSTROPHY 1
Phase: PHASE1, PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Could a common diabetes drug ease muscle problems in Steinert's disease?
Symptom relief Recruiting nowThis phase 3 trial is testing whether metformin, a common diabetes drug, can improve muscle function in adults with myotonic dystrophy type 1 (Steinert's disease). The study will enroll 142 participants who will receive either metformin or a placebo for 6 months. Researchers will…
Matched conditions: MYOTONIC DYSTROPHY 1
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Symptom relief
Last updated Jun 27, 2026 07:59 UTC
-
700-Patient study seeks key clues to muscle disease
Knowledge-focused Recruiting nowThis study is following 700 adults with myotonic dystrophy type 1 (DM1) over two years. Researchers are measuring walking speed, lung function, and muscle tissue changes to find reliable markers of disease progression. The goal is to improve future clinical trials by better under…
Matched conditions: MYOTONIC DYSTROPHY 1
Sponsor: Virginia Commonwealth University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Spanish researchers launch massive DM1 registry to unlock disease secrets
Knowledge-focused Recruiting nowThis study aims to create a national registry for people with Myotonic Dystrophy Type 1 (DM1) in Spain. Researchers will collect clinical data, genetic information, and patient reports from up to 3,000 participants. The goal is to better understand the disease and identify people…
Matched conditions: MYOTONIC DYSTROPHY 1
Sponsor: Fundació Institut Germans Trias i Pujol • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC